Savara Inc. Stock
Savara Inc. Stock
Pros and Cons of Savara Inc. in the next few years
Pros
Cons
Performance of Savara Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Savara Inc. | -1.220% | - | - | - | - | - | - |
Rockwell Medical Inc. | 3.250% | 4.362% | 20.160% | -23.565% | -4.787% | -79.212% | -96.618% |
Avid Bioservices Inc | -1.200% | 0.000% | 38.655% | -38.889% | 35.246% | -49.695% | 161.159% |
Gritstone Oncology Inc | -1.880% | 8.748% | 10.797% | -57.948% | -58.854% | -89.738% | - |
News
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On May 14, 2024
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and